| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 72.7 | 61.2 |
| Gross profit | 54.0 | 45.3 |
| Profit before tax | -6.0 | -11.9 |
| Net income | -5.9 | -11.8 |
| EPS (diluted, $ a share) | $-0.25 | $-0.50 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +18.6% |
|---|---|
| Gross margin | 74.3% |
| Operating margin | -5.8% |
10-Q filed with the SEC, NASDAQ: KIDS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Orthopediatrics Corp: key numbers
- Share price
- $31.50Close, Nov 16
- Market cap
- $822M
- Shares outstanding
- 26.11MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Orthopediatrics Corp
All →Orthopediatrics Investor Presentation
OrthoPediatrics Corp. filed a formal investor presentation dated October 2026 to be used by executive officers in upcoming meetings with investors and analysts. The presentation includes strategic highlights and non-GAAP financial measures such as Adjusted EBITDA and free cash flow. The filing serves as a Regulation FD disclosure for the company's ongoing investor outreach efforts.
Orthopediatrics Financial Results
OrthoPediatrics reported record Q3 2026 revenue of $72.7 million, a 19% increase year-over-year, driven by strong growth in its Trauma & Deformity and Scoliosis segments. The company also generated positive free cash flow of $1.6 million and raised its full-year 2026 revenue guidance to a range of $270 million to $273 million.
- Term
- Q3 2026
“In the third quarter, we continued to build on the momentum in our business, gaining share in Trauma and Deformity and Scoliosis globally, and continued substantial progress with our OPSB strategy. This quarter, we not only drove revenue growth, but we continued to improve profitability, and generated positive free cash flow. We remain confident in our ability to continue to drive these metrics forward.”
David Bailey, President & CEO
“Our innovation super cycle is an important part of that opportunity, with a strong pipeline of new products coming over the next several years that are expected to deliver higher value and improved capital efficiency. We believe these launches will be an important driver of our financial performance as we bring new solutions to more surgeons and hospitals.”
David Bailey, President & CEO